Military Testosterone Testing Raises Health Policy Questions

The initiative marks a significant expansion for a treatment already surging in popularity. Prescriptions climbed from 7.3 million in 2019 to over 11 million in 2024, driven by telehealth providers and a growing cultural focus on longevity. While proponents, including HHS Secretary Robert F. Kennedy Jr., view the therapy as a vital tool for vitality, the medical community remains cautious. The American Urological Association reports that up to one-third of men currently using testosterone lack a formal diagnosis of deficiency, raising concerns about unnecessary usage.

Endocrinologists emphasize that testosterone is not a panacea for aging or low energy. Dr. Adrian Sandra Dobs of the Johns Hopkins School of Medicine notes that while the therapy is effective for those with confirmed clinical needs, over-replacement carries distinct risks, such as impaired sperm production and potential cardiovascular strain. Experts warn that relying on a single blood test to determine eligibility—a strategy seemingly favored by the military—may overlook the nuanced diagnostic criteria required to avoid medical complications. As the program launches, the primary challenge lies in balancing the goal of peak military performance with the long-term safety of those receiving the treatment.